Beijing introduces measures to promote full-category surgical robots' "employment" in hospitals

China News Service, Beijing, April 7 (reporters Chen Hang, Xu Jing) 《Several Measures of Beijing to Support the High-Quality Development of Innovative Pharmaceutical and Medical Products (2026)》(hereinafter referred to as the Measures) was released on the 7th. The Measures propose that Beijing will promote the entry of surgical robots into hospital use, and accelerate the adoption of surgical robots across all categories—including endoscopic, orthopedics, neurosurgery, interventional procedures, and more. The city will expand full-scenario robotic applications in more hospitals.

According to the Measures, Beijing will layout key directions. In areas such as artificial intelligence prediction, it will develop no fewer than 15 models to speed up candidate drug screening. In the brain-computer interface sector, it will carry out R&D on core components such as high-throughput flexible deep electrodes, develop 512-channel invasive products, and accelerate clinical validation.

The Measures propose that Beijing will expand AI applications. It will support verification of typical scenarios such as “AI + medical devices” and “5G + remote diagnosis and treatment.” It will also support at least 10 R&D achievements to be promoted citywide through national artificial intelligence application pilot bases, and gradually expand to domestic and overseas markets.

The Measures propose that Beijing will speed up AI-enabled drug R&D. It will fully leverage Beijing’s strengths in AI resources and proactively plan key areas including foundational models, AI models for drug discovery and design, core technologies, and more. It will focus on original breakthroughs to provide pharmaceutical and medical product companies with services such as target discovery, protein structure analysis, and virtual screening and optimization of drug molecules.

According to the Measures, Beijing will also support the international promotion of innovative drugs and medical devices. It will support companies in carrying out international certifications and overseas sales, and encourage companies to accelerate international development through approaches such as overseas investment, overseas M&A, and localization cooperation. It will encourage leading companies to take the lead in forming overseas cooperation alliances and international cooperation partners’ consortia, leveraging advantages in overseas sales channels and commercialization experience to drive more companies to go abroad together. (End)

(Editor: Wen Jing)

Key words: